Kailera Therapeutics
Clinical-stage biopharmaceutical company developing a differentiated portfolio of injectable and oral therapies for the treatment of obesity and related metabolic conditions.
Notes
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for obesity and related metabolic conditions. The company launched in October 2024 with an industry-leading $400 million Series A financing, one of the largest Series A rounds in biotech history.
Kailera's lead program KAI-9531 (developed in China as HRS9531) is an injectable dual GLP-1/GIP receptor agonist that has demonstrated positive clinical trial results in obesity and type 2 diabetes. The company is also developing oral therapies for weight management.
In November 2025, the company announced a $600 million Series B financing to further advance its pipeline.
Team
- Ron Renaud - President & Chief Executive Officer (former CEO of Cerevel Therapeutics)
- LinkedIn: linkedin.com/in/ronrenaud
- Laurie Stelzer - Chief Financial Officer
- John F. Milligan, Ph.D. - Board Chair (former CEO of Gilead Sciences)
- Frank K. Clyburn, Jr. - Board Director
- Michael Gladstone - Board Director (Partner, Atlas Venture)
Additional Research Findings
- Backed by Bain Capital Life Sciences, Atlas Venture, RTW Investments, and Lyra Capital
- $400 million Series A (October 2024) - one of largest in biotech history
- $600 million Series B (November 2025)
- Lead candidate KAI-9531 is a dual GLP-1/GIP receptor agonist
- Developing both injectable and oral obesity therapies
- Targeting the obesity drug market projected to exceed $150 billion by early 2030s
- Headquarters in Waltham, MA with additional operations in San Diego, CA